Having your say
We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.
You can respond to a consultation by writing to the address in the consultation letter.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like withheld.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA.
16 January 2020 PHARMAC is seeking feedback on a proposal to list a range of obstetrics and gynaecology products in Part III of Section H of the Pharmaceutical Schedule from 1 March 2020 through a provisional agreement with Hologic (Australia & New Zealand) Pty Limited.
Closes: 4pm on Tuesday 4 February 2020.
15 January 2020 We are seeking feedback on a proposal to fund a new topical psoriasis medicine, betamethasone dipropionate with calcipotriol foam spray (Enstilar) from 1 April 2020, through a provisional agreement with Leo Pharma.
Closes: 5pm, Monday 3 February 2020.
15 January 2020 We are seeking feedback on a proposal to fund palbociclib (Ibrance) as a first-line and second-line treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer through a provisional agreement with Pfizer New Zealand.
Closes: 5pm, Friday 31 January 2020.
13 January 2020 PHARMAC is seeking feedback on a proposal to list rehabilitation equipment, patient positioning products and supports supplied by Protec Solutions Limited in Part III of Section H of the Pharmaceutical Schedule from 1 March 2020.
Closes: 4pm on Friday 31 January 2020.
18 December 2019 We are seeking feedback on a proposal to fund mepolizumab (Nucala), a new treatment for severe refractory eosinophilic asthma, from 1 April 2020 through a provisional agreement with GlaxoSmithKline NZ Limited (GSK).
17 December 2019 To help make our decision-making process clearer, we are seeking feedback on a proposal for PHARMAC to make decisions to decline specified inactive funding applications.
16 December 2019 We are seeking feedback on a proposal to widened funded access to lenalidomide (Revlimid) to include maintenance treatment for people with newly diagnosed multiple myeloma (a type of blood cancer) who have undergone autologous stem cell transplant (auto-SCT), through a provisional agreement with Celgene Pty Limited.
Closes: 5pm, Friday 17 January 2020.
9 December 2019 PHARMAC are seeking feedback on proposals to widen funded access to medicines in the blood, alimentary and immunosuppressant therapy areas.
Closes: 4pm Monday, 6 January 2020.
28 November 2019 PHARMAC is seeking your feedback on the proposal to make changes to the funded brands of labetalol tablets, which are used in the treatment of hypertension in pregnancy.
Closes: 4pm, Monday 16 December 2019.
27 November 2019 PHARMAC is seeking feedback on a proposal relating to how we fund discarded medicines (“wastage”) in community pharmacies.
Closes: 5 pm on Friday, 20 December 2019.
Last updated: 19 August 2016